%0 Journal Article
%T Phase II trial of a nonİ\platinum triplet for patients with advanced nonİ\small cell lung carcinoma (NSCLC) overexpressing ERCC1 messenger RNA
%A Daiki Ogawara
%A Hiroaki Senju
%A Hirofumi Nakano
%A Hiroshi Gyoutoku
%A Hiroshi Mukae
%A Hiroyuki Yamaguchi
%A Katsumi Nakatomi
%A Minoru Fukuda
%A Seiji Nagashima
%A Shinnosuke Takemoto
%A Shinya Tomari
%A Shuntaro Sato
%A Takaya Ikeda
%A Takeshi Kitazaki
%A Yoichi Nakamura
%J Archive of "Thoracic Cancer".
%D 2019
%R 10.1111/1759-7714.12958
%X We prospectively evaluated the efficacy and toxicity of a nonİ\platinum triplet regimen for patients with advanced nonİ\small cell lung cancer (NSCLC) expected to be platinumİ\resistant
%K Bevacizumab
%K excision repair crossİ\complementation group 1
%K irinotecan
%K nonİ\small cell lung cancer
%K paclitaxel
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6397920/